ClinicalTrials.gg
CompletedNCT00063141Updated Apr 12, 2010

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

A Phase 3 interventional study of cetuximab and Irinotecan in Colorectal Cancer, sponsored by Eli Lilly and Company. Completed at 188 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-04-12.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,302
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
5th of 185
1,302 · median 60
Started
2003
with 5 others
Phase 3
29 of 187
5 open now
Registered
8th of 187
by date
Lead sponsor
7 of 187
Eli Lilly and Company

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 5th largest by enrollment of the 185 interventional ones that give a count, is one of 6 that started in 2003, is one of 29 in phase 3, and was the 8th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan compared with irinotecan alone as second-line therapy following treatment with a fluoropyrimidine and oxaliplatin based, non-irinotecan-containing regimen.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented colorectal cancer which is EGFR-positive by immunohistochemistry [IHC] (may be based on ) and is .
  • Prior oxaliplatin administered for the treatment of metastatic colorectal cancer.
  • Prior fluoropyrimidine-containing regimen (5-fluorouracil [5-FU], capecitabine, or uracil/tegafur [UFT]), for the first-line treatment of metastatic disease.

Exclusion criteria

Exclusion Criteria:

  • A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy
  • Unresolved diarrhea, bowel obstruction, or history of inflammatory bowel disease
  • Known or documented
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,302 participants (actual)

Study arms

  • Experimental
    Arm A

    Drug: cetuximab · Drug: Irinotecan

  • Active comparator
    Arm B

    Drug: Irinotecan

Interventions

  • Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision

    Also known as: Erbitux

  • Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision

  • Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: Every 3 months after subject off-treatment

Secondary outcomes

  1. Progression Free Survival

    Time frame: Q6 Weeks

  2. Response

    Time frame: Q6 Weeks

  3. Duration of Response

    Time frame: Q6 Weeks

  4. Time to Response

    Time frame: Q6 Weeks

  5. Disease Control Rate

    Time frame: Q6 Weeks

  6. Safety

    Time frame: Q3 Weeks

  7. Quality of Life

    Time frame: Q6 Weeks

  8. Health Economics

    Time frame: Q3 Weeks

07

Study locations

188 sites
  • ImClone Investigational Site
    Tucson, Arizona 85712, United States
  • ImClone Investigational Site
    Pine Bluff, Arkansas 71603, United States
  • ImClone Investigational Site
    Bakersfield, California 93309, United States
  • ImClone Investigational Site
    Berkeley, California 94704, United States
  • ImClone Investigational Site
    Beverly Hills, California 90211, United States
  • ImClone Investigational Site
    Corona, California 92708, United States
  • ImClone Investigational Site
    Gilroy, California 95020, United States
  • ImClone Investigational Site
    Greenbrae, California 95904, United States
  • ImClone Investigational Site
    Long Beach, California 90813, United States
  • ImClone Investigational Site
    Los Angeles, California 90033, United States
  • ImClone Investigational Site
    Los Angeles, California 90057, United States
  • ImClone Investigational Site
    Montebello, California 90640, United States
  • ImClone Investigational Site
    Orange, California 92868, United States
  • ImClone Investigational Site
    Palm Springs, California 92262, United States
  • ImClone Investigational Site
    Rancho Mirage, California 92270, United States
  • ImClone Investigational Site
    San Diego, California 92120, United States
  • ImClone Investigational Site
    Stockton, California 95204, United States
  • ImClone Investigational Site
    Vallejo, California 94589, United States
  • ImClone Investigational Site
    Aurora, Colorado 80012, United States
  • ImClone Investigational Site
    Denver, Colorado 80218, United States
  • ImClone Investigational Site
    New Haven, Connecticut 06520, United States
  • ImClone Investigational Site
    New London, Connecticut 06320, United States
  • ImClone Investigational Site
    Norwich, Connecticut 06360, United States
  • ImClone Investigational Site
    Stamford, Connecticut 06902, United States
  • ImClone Investigational Site
    Fort Myers, Florida 33901, United States
  • ImClone Investigational Site
    Fort Myers, Florida 33990, United States
  • ImClone Investigational Site
    Inverness, Florida 34452, United States
  • ImClone Investigational Site
    Jacksonville, Florida 32207, United States
  • ImClone Investigational Site
    Jacksonville, Florida 32209, United States
  • ImClone Investigational Site
    Jacksonville, Florida 32224, United States
  • ImClone Investigational Site
    Lakeland, Florida 33805, United States
  • ImClone Investigational Site
    Miami, Florida 33136, United States
  • ImClone Investigational Site
    New Port Richey, Florida 34652, United States
  • ImClone Investigational Site
    Orlando, Florida 32806, United States
  • ImClone Investigational Site
    Port St. Lucie, Florida 34952, United States
  • ImClone Investigational Site
    Atlanta, Georgia 30309, United States
  • ImClone Investigational Site
    Atlanta, Georgia 30322, United States
  • ImClone Investigational Site
    Columbus, Georgia 31902-0951, United States
  • ImClone Investigational Site
    Macon, Georgia 31201, United States
  • ImClone Investigational Site
    Savannah, Georgia 31405, United States
  • ImClone Investigational Site
    Tucker, Georgia 30342, United States
  • ImClone Investigational Site
    Honolulu, Hawaii 96813, United States
  • ImClone Investigational Site
    Naperville, Illinois 60540, United States
  • ImClone Investigational Site
    South Bend, Indiana 46601, United States
  • ImClone Investigational Site
    Kansas City, Kansas 66160, United States
  • ImClone Investigational Site
    Overland Park, Kansas 66214, United States
  • ImClone Investigational Site
    Lexington, Kentucky 40536-0098, United States
  • ImClone Investigational Site
    Louisville, Kentucky 40202, United States
  • ImClone Investigational Site
    Richmond, Kentucky 40475, United States
  • ImClone Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • ImClone Investigational Site
    Lafayette, Louisiana 70506, United States
  • ImClone Investigational Site
    Metairie, Louisiana 70006, United States
  • ImClone Investigational Site
    Shreveport, Louisiana 71103, United States
  • ImClone Investigational Site
    Baltimore, Maryland 21204, United States
  • ImClone Investigational Site
    Frederick, Maryland 21701, United States
  • ImClone Investigational Site
    Boston, Massachusetts 02135, United States
  • ImClone Investigational Site
    Ann Arbor, Michigan 48106, United States
  • ImClone Investigational Site
    Detroit, Michigan 48201, United States
  • ImClone Investigational Site
    Southfield, Michigan 48075, United States
  • ImClone Investigational Site
    Minneapolis, Minnesota 55407-3799, United States
  • ImClone Investigational Site
    Robbinsdale, Minnesota 55422, United States
  • ImClone Investigational Site
    St. Louis Park, Minnesota 55426, United States
  • ImClone Investigational Site
    Jackson, Mississippi 39202, United States
  • ImClone Investigational Site
    Kansas City, Missouri 64111, United States
  • ImClone Investigational Site
    Rolla, Missouri 65401, United States
  • ImClone Investigational Site
    St. Louis, Missouri 63110, United States
  • ImClone Investigational Site
    Trenton, New Jersey 08690, United States
  • ImClone Investigational Site
    Voorhees, New Jersey 08084, United States
  • ImClone Investigational Site
    Albany, New York 12208, United States
  • ImClone Investigational Site
    Bronx, New York 10466, United States
  • ImClone Investigational Site
    East Setauket, New York 11733, United States
  • ImClone Investigational Site
    Latham, New York 12110, United States
  • ImClone Investigational Site
    Mineola, New York 11501, United States
  • ImClone Investigational Site
    New York, New York 10016, United States
  • ImClone Investigational Site
    Rexford, New York 12148, United States
  • ImClone Investigational Site
    Stony Brook, New York 11794, United States
  • ImClone Investigational Site
    Valhalla, New York 10595, United States
  • ImClone Investigational Site
    Durham, North Carolina 27710, United States
  • ImClone Investigational Site
    Greenville, North Carolina 27834, United States
  • ImClone Investigational Site
    High Point, North Carolina 27262, United States
  • ImClone Investigational Site
    Raleigh, North Carolina 27609, United States
  • ImClone Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • ImClone Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • ImClone Investigational Site
    Bismarck, North Dakota 58501, United States
  • ImClone Investigational Site
    Cincinnati, Ohio 45267, United States
  • ImClone Investigational Site
    Cleveland, Ohio 44106, United States
  • ImClone Investigational Site
    Columbus, Ohio 43235, United States
  • ImClone Investigational Site
    Dayton, Ohio 45459, United States
  • ImClone Investigational Site
    Newark, Ohio 43055, United States
  • ImClone Investigational Site
    Oklahoma City, Oklahoma 73118, United States
  • ImClone Investigational Site
    Hershey, Pennsylvania 17033, United States
  • ImClone Investigational Site
    Philadelphia, Pennsylvania 19106, United States
  • ImClone Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • ImClone Investigational Site
    Philadelphia, Pennsylvania 19141-3098, United States
  • ImClone Investigational Site
    Pittsburgh, Pennsylvania 15232, United States
  • ImClone Investigational Site
    Greenville, South Carolina 29615, United States
  • ImClone Investigational Site
    Knoxville, Tennessee 37916, United States
  • ImClone Investigational Site
    Memphis, Tennessee 38120, United States
  • ImClone Investigational Site
    Nashville, Tennessee 37203, United States
  • ImClone Investigational Site
    Austin, Texas 78759, United States

Showing the first 100 of 188 sites across 17 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003, a primary completion of Jun 2006 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2003
First posted
Jun 25, 2003
Start
Apr 2003
Primary completionActual
Jun 2006
CompletionActual
Oct 2007
Last update
Apr 12, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00063141
First posted
Jun 25, 2003
Start date
Apr 2003
Primary completion
Jun 2006
Completion
Oct 2007
Last update
Apr 12, 2010

Study contacts

E-mail: ClinicalTrials@ ImClone.com
study chair · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion